Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

Three young girls at a clinic in Asia © Credit: Rama George-Alleyne, World Bank

The study identified 135 clinical treatment trials of visceral leishmaniasis published in the past 40 years enrolling 32,177 patients of whom 21,193 (65.9%) were male and 10,984 (34.1%) female, overwhelmingly from high-burden countries of the Indian subcontinent and Eastern Africa.

Visceral leishmaniasis is a neglected tropical disease that currently has an annual estimated incidence of 50,000 to 90,000 cases in 2019 but the case burden used to be much higher. This drop is mostly the result of the ongoing elimination campaign that begun in the Indian subcontinent in 2005.

The Infectious Diseases Data Observatory (IDDO) is currently working towards collating and standardising datasets from several clinical studies included in this systematic review which could provide a valuable resource to understand if differences in treatment outcomes can be expected and what the underlying factors might be.

The full story is available on the IDDO website

Read the publications: Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: a systematic review and meta-analysis

Similar stories

Oxford University launch new clinical trial to test a treatment for monkeypox

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox. The National Institute for Health and Care Research (NIHR) has commissioned and funded the study. The first patients have now been recruited.

Using mathematical modelling to fight malaria

Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.

FORESFA and VIE project meetings

The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.

Incomplete reporting of COVID-19 disease severity criteria compromises meta-analysis

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.

A multi-country study of monkeypox being launched – first cases enrolled in Geneva

Researchers have launched a new study to improve our understanding of monkeypox disease. The first patients have now been recruited at Hôpitaux Universitaires de Genève (HUG) in Switzerland

Pandemic Sciences Institute formally launched in Oxford

The University of Oxford’s Pandemic Sciences Institute (PSI) has been formally launched at a two-day event at the Blavatnik School of Government, at which the lead researchers set out its direction and strategy for the next five years.The PSI will draw together academics and experts from across the University to build a multi-disciplinary institute focused on reducing the risk from infectious threats through science, innovation and building global preparedness.